180 related articles for article (PubMed ID: 25319493)
1. The effects of oncolytic reovirus in canine lymphoma cell lines.
Hwang CC; Umeki S; Igase M; Coffey M; Noguchi S; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():61-73. PubMed ID: 25319493
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic reovirus in canine mast cell tumor.
Hwang CC; Umeki S; Kubo M; Hayashi T; Shimoda H; Mochizuki M; Maeda K; Baba K; Hiraoka H; Coffey M; Okuda M; Mizuno T
PLoS One; 2013; 8(9):e73555. PubMed ID: 24073198
[TBL] [Abstract][Full Text] [Related]
3. The oncolytic effects of reovirus in canine solid tumor cell lines.
Igase M; Hwang CC; Coffey M; Okuda M; Noguchi S; Mizuno T
J Vet Med Sci; 2015 May; 77(5):541-8. PubMed ID: 25648933
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
6. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines.
Hwang CC; Igase M; Okuda M; Coffey M; Noguchi S; Mizuno T
Biochem Biophys Res Commun; 2019 Sep; 517(2):233-237. PubMed ID: 31345575
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.
Igase M; Hwang CC; Kambayashi S; Kubo M; Coffey M; Miyama TS; Baba K; Okuda M; Noguchi S; Mizuno T
Can J Vet Res; 2016 Jan; 80(1):21-31. PubMed ID: 26733729
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Ema Y; Igase M; Takeda Y; Yanase T; Umeki S; Hiraoka H; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():95-106. PubMed ID: 25623777
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of mantle cell lymphomas to reovirus oncolysis.
Alain T; Muzik H; Otsuka S; Chan S; Magliocco T; Diaz R; Forsyth PA; Morris D; Bebb G
Leuk Res; 2010 Jan; 34(1):100-8. PubMed ID: 19651440
[TBL] [Abstract][Full Text] [Related]
10. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
[TBL] [Abstract][Full Text] [Related]
15. Noncanonical Cell Death Induction by Reassortant Reovirus.
Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
[TBL] [Abstract][Full Text] [Related]
16. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma.
Alloussi SH; Alkassar M; Urbschat S; Graf N; Gärtner B
Oncol Rep; 2011 Sep; 26(3):645-9. PubMed ID: 21637921
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
18. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.
Garant KA; Shmulevitz M; Pan L; Daigle RM; Ahn DG; Gujar SA; Lee PW
Oncogene; 2016 Feb; 35(6):771-82. PubMed ID: 25961930
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
